Platelet depletion, platelet activation and coagulation during treatment with hemodialysis

Abstract Bioincompatibility is the total of side effects during hemodialysis (HD) including, amongst others, changes in platelet (PLT) level. Deviations in PLT count, immature PLT count, PLT morphology, CD62p expression, Platelet Factor 4 (PF4), β-Thromboglobulin (β-TG), serotonin, Thrombin-Antithro...

Full description

Saved in:
Bibliographic Details
Published in:Scandinavian journal of clinical and laboratory investigation 2011-05, Vol.71 (3), p.240-247
Main Authors: Schoorl, Marianne, Schoorl, Margreet, Nubé, Menso J., Bartels, Piet C. M.
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Antithrombin III
beta-Thromboglobulin - metabolism
Biological and medical sciences
Biomarkers - blood
Blood Coagulation
Blood Platelets - pathology
Cell density
Cell Shape
coagulation
Emergency and intensive care: renal failure. Dialysis management
hemodialysis
Humans
Intensive care medicine
Investigative techniques, diagnostic techniques (general aspects)
Medical sciences
Middle Aged
Nephrology. Urinary tract diseases
Nephropathies. Renovascular diseases. Renal failure
P-Selectin - blood
Peptide Fragments - blood
Peptide Hydrolases - blood
Platelet Activation
Platelet Count
platelet depletion
Platelet Factor 4 - blood
Prothrombin
Renal Dialysis - adverse effects
Renal failure
Renal Insufficiency, Chronic - blood
Renal Insufficiency, Chronic - therapy
Serotonin - blood
Thrombosis - etiology
uremia
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Bioincompatibility is the total of side effects during hemodialysis (HD) including, amongst others, changes in platelet (PLT) level. Deviations in PLT count, immature PLT count, PLT morphology, CD62p expression, Platelet Factor 4 (PF4), β-Thromboglobulin (β-TG), serotonin, Thrombin-Antithrombin III (TAT) and Prothrombin Fragment 1+2 (F1+2) are monitored before and during treatment with HD in order to elucidate the interaction between modifications in PLT morphology, PLT activation and markers concerning activation of coagulation. Different patterns with time indicate that there is no correlation between an increased amount of depleted PLTs and increased amounts of PLT activation markers such as CD62p, PF4, β-TG and serotonin. A statistically significant correlation between increased PLT activation markers and markers for increased activation of coagulation such as TAT and F1+2 has not been established. Only a weak correlation is demonstrated between the increase of markers for activation of coagulation and the decrease in PLT counts, immature PLT counts and depleted PLTs during HD treatment. The change in the extracorporeal circuit during HD is probably a more critical factor in the mechanism leading to activation of the coagulation pathway than the modifications in PLT morphology.
ISSN:0036-5513
1502-7686
DOI:10.3109/00365513.2011.558106